Cell engineering

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapy

Retrieved on: 
Monday, May 22, 2023
University, UW, Biochemistry, Fred Hutchinson Cancer Research Center, Infection, Clinical and Translational Science Award, Howard Hughes Medical Institute, Research, Doctor of Philosophy, Breakthrough Prize in Life Sciences, CAR, MD, Patient, Machine learning, University of Washington School of Medicine, Algorithm, Cancer, Drug discovery, Burke, Cell engineering, Therapy, Pharmaceutical industry, Oncology, Immunotherapy, Medicine

This expansion will accelerate the company’s efforts to turn cell therapies into safe and effective cures for patients.

Key Points: 
  • This expansion will accelerate the company’s efforts to turn cell therapies into safe and effective cures for patients.
  • "Seattle is home to some of the world's leading biomedical institutions, and we look forward to growing into this community," said Marc Lajoie , CEO and co-founder of Outpace Bio.
  • "Together, these collaborations will help advance our mission to create safe and effective cell therapies."
  • Dr. Baker has co-founded multiple biotechnology companies, published over 600 research articles, and is a named inventor on more than 100 patents related to protein design.

Outpace Bio to Present New Data on OutSmart™ IL-2/15, a CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity, at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Thursday, May 18, 2023
Gene, Survival, Cancer, NK, Toxicity, Gene expression, Cell, Doctor of Philosophy, CAR, Outline, Patient, Risk, TME, Neoplasm, Cytokine, Cell engineering, Abstract, Tumor microenvironment, Society, Safety, Vaccine, Regulatory T cell

Pro-inflammatory cytokines could overcome the TME but pose a significant safety risk to patients when delivered systemically given their potency.

Key Points: 
  • Pro-inflammatory cytokines could overcome the TME but pose a significant safety risk to patients when delivered systemically given their potency.
  • Cell therapies engineered with OutSmart™ technology produce the right signals inside the tumor and keep them there.
  • With OutSmart™, the cell therapy bolsters its own activity while also recruiting helpful bystander cells to achieve efficacy without compromising safety.
  • Antigen targeting provides additional control by retaining the cytokine near the tumor and addressing activity to specific cell populations.

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

Retrieved on: 
Wednesday, May 17, 2023
DNA, Euronext Growth, Arm, ASH, Gene, CRS, Relapse, Neoplasm, Gene editing, Bone marrow, UCART123, Cyclophosphamide, FC, Cmax, Allotransplantation, DL2, Acute myeloid leukemia, MRD, CAR, AML, Patient, AUC, Annual general meeting, Alemtuzumab, Cytokine release syndrome, Cell, TGFB1, CR, FCA, American Society of Gene and Cell Therapy, Multi, Infrared spectroscopy correlation table, Cell engineering, PD-1, Safety, Tumor microenvironment, Society, Disease, Vaccine, Pharmaceutical industry, Medical imaging, Cellectis

Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.

Key Points: 
  • Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.
  • The preclinical data demonstrate that multiplexed engineering does not compromise CAR T-cell function, which can even be enhanced and display improved anti-tumor activity.
  • These preclinical data show that we can precisely select and combine an array of gene and cell engineering approaches to produce armored CAR T-cells with high efficiency rates.
  • TALEN® and TALE-BE technologies can be integrated in the generation of CAR T-cells to provide high gene editing rates while preserving genomic safety.

Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Tuesday, May 9, 2023
CAR, Cell engineering, Doctor of Philosophy, Gene, Tumor microenvironment, Society, American Society of Gene and Cell Therapy, Cell, Pharmaceutical industry, Vaccine

Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an abstract was selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual meeting being held from May 16-20, 2023 in Los Angeles, CA.

Key Points: 
  • Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an abstract was selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual meeting being held from May 16-20, 2023 in Los Angeles, CA.
  • “We look forward to presenting advancements from our OutSmartTM platform at ASGCT later this month that highlight our ability to combine protein design and cell engineering to overcome key barriers in the treatment of solid tumors with CAR T cells”, said Aaron Foster, PhD , Chief Scientific Officer of Outpace Bio.
  • “We are highly encouraged by our preclinical data demonstrating that CAR T cells can produce a computationally designed cytokine, OutSmartTM IL-2/15, in a context-dependent manner that drives CAR T expansion while minimizing activation of immune suppressive regulatory T cells.
  • The OutSmartTM system has the potential to overcome solid tumor barriers by enhancing CAR T cell persistence and stimulating productive immune responses within the tumor microenvironment while reducing IL-2 related side-effects.”

Outpace Bio, a Leader in Protein Design for Cell Therapy, Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, May 4, 2023
Differentiable function, University, Biotechnology, Senior, IPSC, Center for Cell and Gene Therapy, Bone marrow, Baylor University, Cancer, Partner (business rank), Research, Infection, Bayer, Doctor of Philosophy, McKinsey & Company, Science, CAR, Rose–Hulman Institute of Technology, Acquisition, Patent, Cell, Drug discovery, Baylor College of Medicine, Cell engineering, Cardiology, Therapy, IND, Neurology, Gene therapy, Massachusetts Institute of Technology, Pharmaceutical industry

Seattle, WA, May 04, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies, today announced two key leadership appointments.

Key Points: 
  • Seattle, WA, May 04, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies, today announced two key leadership appointments.
  • The appointments bolster Outpace’s mission to develop technologies that overcome the barriers standing in the way of effective and safe cell therapies for cancer.
  • “We launched Outpace to unleash the full power of cell therapies by combining the groundbreaking fields of de novo protein design and cell engineering, and I'm thrilled that Aaron and Eric have joined us on this mission,” said Marc Lajoie, PhD , CEO and co-founder of Outpace.
  • “Cell therapies have shown tremendous benefits for blood cancers, but similar results for solid tumors have lagged behind” said Dr. Foster.

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, May 4, 2023
NTLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellia Therapeutics, Retirement, Acquisition, Patient, Ventilator-associated lung injury, ESG, Cardiomyopathy, Cell engineering, Disease, Tissue, Corporate social responsibility, Gene editing, Research, NK, Social Security Government Pension Offset, AATD, Corporation, Liver, Social, FDA, Conference, Safety, D, DNA, Health care, SERPINA1, HAE, ATM, Therapy, MHRA, CRISPR, Liver disease, Hereditary angioedema, KLKB1, TTR, ATTR, A1AT, Amyloidosis, Banc of America Securities (1998–2008), Bank, Food, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Video game, IND

Subject to regulatory feedback, the Company anticipates initiating a global pivotal trial for ATTR-CM by year-end 2023.

Key Points: 
  • Subject to regulatory feedback, the Company anticipates initiating a global pivotal trial for ATTR-CM by year-end 2023.
  • The Company plans to present additional clinical data from the ATTRv-PN arm of the Phase 1 study in 2023.
  • Based on encouraging study interest from both investigators and patients, the Company expects to complete enrollment (n=25) in 2H 2023.
  • The Company will discuss these results on a conference call today, Thursday, May 4, at 8 a.m.

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

Retrieved on: 
Thursday, May 4, 2023
LSE, Partnership, Therapy, Walking fish, Biotechnology, SPL, Walking, Autoimmune disease, Cell engineering, Fabry disease, Fine chemical, Pharmaceutical industry, Vaccine, Fish

Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are delighted to partner with Walking Fish to help advance their B cell platform and support their innovative approach to develop novel therapies for the treatment of serious diseases,” said Doug Doerfler, President and CEO of MaxCyte.
  • Walking Fish is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators.
  • Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production.

Sepion Technologies Appoints Dr. Brian C. Sisk as CTO to Drive Product Development and Partnerships

Retrieved on: 
Tuesday, May 2, 2023
Automotive, Automotive Manufacturing, EV, Electric Vehicles, Technology, Batteries, Manufacturing, Hardware, BS, Doctor of Philosophy, Dundee Cell Products, Sherlock Automated Design Analysis, California Institute for Telecommunications and Information Technology, MHEV, A123 Systems, SUV, R1T, EVS, Amazon, Ballarat Energy Storage System, Algorithm, Knowledge, Growth, Entrepreneurship, Cell engineering, Lithium, Electric battery, California Institute of Technology, Sisk, Western Kentucky University, Chemistry, Rivian, A123

In this role, Sisk will oversee Sepion's battery materials development, cell engineering, and strategic partnerships.

Key Points: 
  • In this role, Sisk will oversee Sepion's battery materials development, cell engineering, and strategic partnerships.
  • Prior to Rivian, Sisk served as Vice President of Cell Product Development at A123 Systems where he contributed to the company's market leadership for low-voltage 48V and 12V automotive batteries.
  • "I am excited to join Sepion Technologies and work with the accomplished team here to drive innovation and bring new products to market," noted Sisk.
  • For more information about Sepion Technologies, visit its website at Sepiontechnologies.com or on LinkedIn and Twitter .

NanoFCM Partners with RoosterBio as an Approved Service Provider for Exosome Analysis

Retrieved on: 
Wednesday, April 26, 2023
Partnership, Therapy, Exosome, Research, Flow cytometry, Knowledge, Cell engineering, Medical imaging, EV

FREDERICK, Md., April 26, 2023 /PRNewswire-PRWeb/ -- NanoFCM Co., Ltd today announced that RoosterBio, Inc. a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, is approved to provide analytical services worldwide using NanoFCM's NanoAnalyzer.

Key Points: 
  • In this strategic partnership, RoosterBio becomes the first US-based service provider approved by NanoFCM to perform contract analytical services using the NanoAnalyzer platform.
  • In this strategic partnership, RoosterBio becomes the first US-based service provider approved by NanoFCM to perform contract analytical services using the NanoAnalyzer platform.
  • Traditional methods for exosome characterization have been limited to population-level analysis, while conventional flow cytometry lacks the sensitivity required for single nanoparticle analysis.
  • "We are delighted to be selected as an approved provider for state-of-the-art exosome analytical characterization using NanoFCM's NanoAnalyzer technology," said Tim Kelly, Chief Executive Officer of RoosterBio.

Daniel Li Joins SES as Chief Manufacturing Officer

Retrieved on: 
Wednesday, April 26, 2023
Technology, Other Energy, Manufacturing, Automotive, Batteries, Trucking, Alternative Energy, Energy, Transport, Environment, Other Automotive, Hardware, Other Manufacturing, Green Technology, Daniel, International Generic Sample Number, EV, Multimedia, MIT, EVS, SES, Business Wire, Cell engineering, OEM, NYSE, Electric battery, Lithium, A123

SES AI Corporation (NYSE: SES), headquartered in Boston, a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced the appointment of Daniel Li as Chief Manufacturing Officer.

Key Points: 
  • SES AI Corporation (NYSE: SES), headquartered in Boston, a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced the appointment of Daniel Li as Chief Manufacturing Officer.
  • Mr. Li has been working in the lithium-ion battery industry for 15 years, including in senior roles at A123.
  • “SES is the clear leader in Li-Metal battery technology, and I am excited to join the organization and help lead the commercialization of the cutting-edge technology, including the transition from A-Samples to B-Samples beginning this year,” said Chief Manufacturing Officer Daniel Li.
  • Daniel will help SES accelerate the commercialization of Li-Metal and help SES become the leader for next-generation EV and eVTOL batteries.